Clinical trials: Female Breast Neoplasms
Breast Cancer Female
Molecular Imaging of HER2 Expression in HER2-positive Breast Cancer Using 99mTc-ADAPT6 vs 99mTc-DARPinG3
An open-label, single center study with 99mTc-ADAPT6 and 99mTc-DARPinG3 SPECT and biopsies of primary tumour in HER2-positive Breast Cancer before system (chemo/targeted) therapy, where the primary endpoint of the study is to…
- Trial name
- NCT05376644
- Testing
- 99mTc-ADAPT6, 99mTc-DARPinG3
- Where
- Russia
- Volunteers
- 15 people
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Metastatic Breast Cancer
Study to Determine the Utility of FES-PET and FDG-PET in the Prediction of Response to Hormone Therapy in Women With Estrogen Positive Metastatic Breast Cancer
This study of hormone positive (estrogen receptor [ER]), metastatic invasive ductal breast cancer looks at functional scanning using positron emission tomography (PET) and patient response to hormone therapy.
- Trial name
- NCT00358098
- Where
- Canada
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- AHS Cancer Control Alberta
Breast Cancer Female, Depression
Moving on After Breast Cancer Plus- for Breast Cancer Survivors
Breast cancer (BC) ranks second among all the types of cancer and is equally common in developing as well as developed countries.
- Trial name
- MovingonABC (NCT03571984)
- Testing
- Moving on ABC Plus
- Where
- Pakistan
- Volunteers
- 354 people
- Sponsor
- Pakistan Institute of Living and Learning
Breast Cancer, Chemotherapeutic Agent Toxicity
G-CSF in Preventing Neutropenia in Women Receiving Chemotherapy for Breast Cancer
RATIONALE: G-CSF may prevent or reduce febrile neutropenia in women receiving chemotherapy for breast cancer. It is not yet known which G-CSF regimen is more effective in preventing neutropenia.
- Conditions
- Breast Cancer, Chemotherapeutic Agent Toxicity, Neutropenia
- Trial name
- NCT00771433
- Testing
- filgrastim
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Centre Francois Baclesse
Advanced Solid Tumor, Unresectable Solid Tumor
A Beta-only IL-2 ImmunoTherapY Study
This is a Phase 1/2, multi-center, open-label, dose-escalation and expansion study to evaluate safety and tolerability, PK, pharmacodynamic, and early signal of anti-tumor activity of MDNA11 alone or in combination with a…
- Conditions
- Advanced Solid Tumor, Unresectable Solid Tumor, Clear Cell Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- ABILITY-1 (NCT05086692)
- Testing
- MDNA11, Pembrolizumab (KEYTRUDA®)
- Where
- 25 sites in United States, Australia and 6 more
- Volunteers
- 160 people
- Sponsor
- Medicenna Therapeutics, Inc.
Male Breast Cancer, Recurrent Breast Cancer
AFP464 in Treating Patients With Metastatic or Refractory Solid Tumors That Cannot Be Removed By Surgery
This phase I trial studies the side effects and best dose of AFP464 in treating patients with metastatic or refractory solid tumors that cannot be removed by surgery.
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Primary Peritoneal Cavity Cancer
- Trial name
- NCT00348699
- Testing
- AFP464, pharmacological study, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 68 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Breast Cancer and Pregnancy
Pregnancy Outcomes After Breast Cancer in Young Women With Germline Pathogenic Variants in Genes Other Than BRCA
The present study aims to refine the understanding of the prognostic impact of pregnancy after breast cancer in young women harboring germline pathogenic variants in breast cancer susceptibility genes other than BRCA
- Trial name
- Beyond BCY (NCT07591532)
- Volunteers
- 2,200 people
- Sponsor
- Jules Bordet Institute
Breast Cancer, Breast Cancer, Early-Onset
Preoperative Window Opportunity Study With Giredestrant or Tamoxifen in Premenopausal Women With ER+/HER2[-] & Ki67≥10%
This study is a window of opportunity clinical trial to evaluate the efficacy of giredestrant (GDC-9545) or tamoxifen in estrogen receptor-positive (ER[+])/human epidermal growth factor receptor 2-negative (HER2[-]) primary…
- Trial name
- EMPRESS (NCT05659563)
- Testing
- Giredestrant, Tamoxifen
- Where
- 18 sites in France, Spain
- Volunteers
- 92 people
- Sponsor
- MedSIR
Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma
A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3)
This is a Phase 1, multiple dose, ascending dose escalation study to define a MTD/RD and regimen of XmAb23104, to describe safety and tolerability, to assess PK and immunogenicity, and to preliminarily assess anti-tumor activity…
- Conditions
- Melanoma (Excluding Uveal Melanoma), Cervical Carcinoma, Pancreatic Carcinoma, Breast Carcinoma That is Estrogen Receptor, Progesterone Receptor, and Her2 Negative
- Trial name
- DUET-3 (NCT03752398)
- Testing
- XmAb®23104, Yervoy® (ipilimumab)
- Where
- 18 sites in United States
- Volunteers
- 198 people
- Sponsor
- Xencor, Inc.
Breast Neoplasm Female
Effects of Training and Detraining on Postmenopausal Breast Cancer Survivors
The present study aimed to verify the effects of resistance exercise training and successive detraining on body composition, lipid profile, muscle strength, oxidative stress, and inflammatory markers of postmenopausal breast…
- Trial name
- NCT04479098
- Testing
- Resistance exercise training, Exercise detraining
- Where
- Brazil
- Volunteers
- 14 people
- Sponsor
- Federal University of Uberlandia
Breast Neoplasms, Neoplasm Metastasis
Study Evaluating CCI-779 and Letrozole in Post-menopausal Women With Breast Cancer
In this clinical research study, postmenopausal subjects with metastatic breast cancer will be given either the combination of temsirolimus (CCI-779) and letrozole or a placebo and letrozole in first-line hormonal treatment.
- Trial name
- NCT00083993
- Testing
- Temsirolimus (CCI-779) for 34 months, Letrozole for 34 months
- Where
- 129 sites in United States, Canada
- Volunteers
- 1,236 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Breast Cancer
Hypofractionated Radiotherapy Post-Lumpectomy in Women With Node Negative Breast Cancer
To determine if hypofractionated radiotherapy to the whole breast (4,250 cGy/16 fractions over 22 days) is equally effective to standard fractionated radiotherapy (5,000 cGy/25 fractions over 35 days) in women with node negative…
- Trial name
- NCT00156052
- Testing
- Conventional whole breast radiation schedule, Hypofractionated whole breast radiation schedule
- Where
- 11 sites in Canada
- Volunteers
- 1,234 people
- Sponsor
- Ontario Clinical Oncology Group (OCOG)
Breast Cancer Female, Acute Leukemia
Use of GnRHa During Chemotherapy for Fertility Protection
Many cytotoxic drugs may harm the fertility of young women treated for cancer. The aim of the study is to investigate if the Gonadotropin-Releasing Hormone agonist (GnRHa) during cancer treatment can preserve the fertility of…
- Conditions
- Breast Cancer Female, Acute Leukemia, Lymphoma, Osteosarcoma
- Trial name
- ProFertil (NCT05328258)
- Testing
- Triptorelin Embonate, Sodium Chloride solution 0.9%
- Where
- 17 sites in Sweden
- Volunteers
- 500 people
- Sponsor
- Kenny Rodriguez-Wallberg
Advanced Breast Cancer, Female Breast Cancer
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
This is a multicenter, randomized, double-blind, placebo-controlled Phase III clinical study evaluating the efficacy and safety of FCN-437c in combination with letrozole or anastrozole ± Goserelin versus placebo combined with…
- Trial name
- NCT05439499
- Testing
- FCN-437c, Letrozole or anastrozole, Goserelin acetate
- Where
- China
- Volunteers
- 434 people
- Sponsor
- Ahon Pharmaceutical Co., Ltd.
Breast Cancer
S0338, Imatinib Mesylate and Capecitabine in Treating Women With Progressive Stage IV Breast Cancer
RATIONALE: Imatinib mesylate may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop tumor cells from dividing so…
- Trial name
- NCT00087152
- Testing
- Capecitabine, Imatinib mesylate
- Volunteers
- 27 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
Longitudinal ctDNA Surveillance for Older Women With ER+ Breast Cancer Who Omit Surgery
This prospective study recruits patients with ER+/HER2-, non-metastatic breast cancer who omit upfront surgery in favor of primary endocrine therapy for sample collection and prospective circulating tumor DNA (ctDNA) measurement…
- Trial name
- NCT05914792
- Where
- United States
- Volunteers
- 49 people
- Sponsor
- University of Pittsburgh
Breast Cancer, Cervical Cancer
Behavioral Intervention Study for Better Breast and Cervical Cancer Control for Korean American Women
The long-term goal of this study is to build a sustainable,community-based outreach program using Korean American community health workers (CHWs) to promote breast and cervical screening among Korean American women, thereby…
- Trial name
- NCT00857636
- Testing
- Health literacy, health message
- Where
- United States
- Volunteers
- 560 people, healthy volunteers welcome
- Sponsor
- Johns Hopkins University
Breast Cancer
High Dose Chemotherapy Plus Peripheral Stem Cell Transplantation Compared With Standard Therapy in Treating Women With Metastatic or Recurrent Breast Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of…
- Trial name
- NCT00003032
- Testing
- filgrastim, cisplatin, cyclophosphamide
- Where
- 25 sites in Canada
- Volunteers
- 224 people
- Sponsor
- NCIC Clinical Trials Group
Breast Neoplasm Female
ePainQ - Feasibility Study
This is a feasibility study of a web-based pain self-management system aimed at providing support for acute postoperative pain and enhancing patient care.
- Trial name
- ePainQ (NCT03638414)
- Testing
- ePainQ questionnaire
- Where
- United Kingdom
- Volunteers
- 25 people
- Sponsor
- The Leeds Teaching Hospitals NHS Trust
Mammary Tumor, Nipple Discharge
A Novel Fluorescent Ductal Needle for Localization and Sampling of High-risk Breast Micro Lesions
This retrospective cohort study investigates the differences in the reliability of rapid pathology compared to postoperative pathology when utilizing a novel fluorescent localization needle equipped with a controllable shedding…
- Trial name
- NCT06994416
- Testing
- novel fluorescent localization marker needle, conventional localization marker needle
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The Fourth Affiliated Hospital of China Medical University
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.